03:33 , Aug 17, 2018 |  BC Week In Review  |  Financial News

Infectious company Aridis raises $26M in NASDAQ IPO

Infectious disease mAb company Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) raised $26 million on Aug. 13 through the sale of 2 million shares at $13 in an IPO on NASDAQ. Cantor Fitzgerald, Maxim Group, Laidlaw, Northland Securities...
15:30 , Jul 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Pseudomonas Cell culture and mouse studies suggest miR-138 or its mimetics could help treat Pseudomonas aeruginosa lung infections. In lung samples from a mouse model of P. aeruginosa lung infection, levels of miR-138 were higher...
23:37 , Jul 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Pseudomonas Cell culture and mouse studies suggest inhaled bacteriophage-loaded microparticles could help treat Pseudomonas aeruginosa lung infections. The microparticles consist of porous poly(lactic-co-glycolic acid) (PLGA) polymer shells loaded with a cocktail of three or five...
18:48 , May 30, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Bacterial infection Cell culture studies suggest nanoparticles loaded with the antibacterial compound carvacrol could help treat bacterial infections. The nanoparticles consist of a poly(oxanorborneneimide) crosslinked with biodegradable dithiol-disulfide and loaded with an emulsion of carvacrol....
00:36 , May 25, 2018 |  BC Innovations  |  Product R&D

Peptides step up

New screening platforms and synthetic approaches could finally solve some of the longstanding hurdles to turning antimicrobial peptides into therapeutic candidates to combat antibacterial resistance, overcoming their history of limited clinical efficacy, systemic toxicity and...
23:28 , May 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious

INDICATION: Gram-negative bacterial infection; Gram-positive bacterial infection; fungal infection Cell culture and mouse studies suggest peptides derived from a guava antimicrobial peptide (AMP) could help treat bacterial and fungal infections. Screening of 15 synthetic peptide analogs...
22:52 , Apr 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer; cervical cancer; gastric cancer; lung cancer; pancreatic cancer Cell culture and mouse studies suggest three mesothelin-targeting chimeric immunotoxins could help treat mesothelin-expressing cancers. The three immunotoxins consist of the variable region a mouse mesothelin-targeting...
01:16 , Mar 30, 2018 |  BC Innovations  |  Finance

Bug money

Despite the tremendous public health need and the introduction of regulatory incentives including expedited review and market exclusivity, venture investing in antibiotics remains modest and focused primarily on clinical assets seeking to improve on known...
18:11 , Jan 12, 2018 |  BC Week In Review  |  Clinical News

AmpliPhi reports data from expanded access program for bacteriophages

AmpliPhi Biosciences Corp. (NYSE-M:APHB) reported data from seven patients with serious, life-threatening infections who did not respond to antibiotics from an expanded access program showing that AB-SA01 or AB-PA01 (Biophage-PR, AmpliPhage-001) in combination with best...
19:32 , Nov 3, 2017 |  BC Week In Review  |  Company News

Microbiotix partners with AMR Centre to develop bacterial virulence inhibitor

Microbiotix Inc. (Worcester, Mass.) partnered with the Antimicrobial Resistance Centre to develop a bacterial virulence inhibitor candidate targeting drug resistant Gram-negative bacteria including Pseudomonas aeruginosa from Microbiotix's T3SS (type III secretion system) inhibitor project. The...